Tecentriq (atezolizumab), in combination with Avastin (bevacizumab), has been recommended for approval in the European Union as a first-line treatment for adults with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer. The recommendation was made by the Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency. The CHMP’s recommendations are generally accepted by the European Commission, which makes the final decisions. “Today’s recommendation by the CHMP is…
You must be logged in to read/download the full post.
The post Tecentriq-Avastin Combo Recommended for EU Approval for Liver Cancer appeared first on BioNewsFeeds.